港股詳情

本頁面由Tiger Fintech (Singapore) Pte. Ltd.提供服務

晶泰控股-P

4.340

-0.160-3.56%

成交量：2,728.52萬

成交額：1.20億

市值：174.47億

市盈率：-5.10

高：4.510

開：4.510

低：4.330

收：4.500

資料載入中...

總覽公司新聞資訊公告

晶泰控股-P：擬配股籌資約20.88億港元

晶泰控股(02228.HK)折讓5.9%配股淨籌20.8億元

阿斯达克财经

晶泰控股(02228.HK)附屬夥廣東恆健推進AI與產業融合創新聯合體項目

阿斯达克财经

晶泰控股-P宣佈配售計劃，總籌20.88億港元資金助力產品升級與市場拓展

晶泰控股-P擬發行最多3.42億股配售股份淨籌20.8億港元

【晶泰控股-P(02228.HK)擬發行最多3.42億股配售股份淨籌20.8億港元】晶泰控股-P(02228.HK)發佈公告，於2025年2月19日，本公司與配售代理訂立配售協議，本公司同意根據一般授權發行，而配售代理同意(個別而非共同或共同及個別)作為本公司的代理，在配售協議的條款及條件規限下，按盡力基準促使承配人按配售價每股配售股份6.10港元認購合共最多3.42億股配售股份。

晶泰控股-P(02228)擬發行最多3.42億股配售股份淨籌20.8億港元

【晶泰控股-P(02228.HK)與廣東恆健積極推進“人工智能+”科技與產業融合創新聯合體項目的落地】晶泰控股-P(02228.HK)發佈公告，近日，本公司全資附屬公司深圳晶泰科技有限公司與廣東恆健投資控股有限公司(廣東恆健)正積極推進“人工智能+”科技與產業融合創新聯合體項目(該項目)的落地，該項目以“AI+機器人自動化”技術為核心，致力於建設全球領先的研發創新基礎設施與產業孵化生態系統，促進戰略性產業集羣化發展，推動粵港澳大灣區及全球相關產業加速實現數字化和智能化革新，助力大灣區打造世界一流的人工智能研究基礎設施，驅動AI醫藥、新材料、新能源、機器人等產業的未來發展。

晶泰控股-P02月18日主力淨流出5190萬元散戶資金買入

晶泰控股－Ｐ(02228)出現大手賣出110萬股，成交價$6.5，涉資715萬

阿斯达克财经

晶泰控股-P(02228)下跌5.11%，報6.5元/股

晶泰控股-P盤中異動快速下挫5.11%報6.500港元

【默達生物獲上億元人民幣A輪融資】深圳默達生物科技有限公司（META Pharmaceuticals Inc.）近日宣佈完成上億元人民幣的A輪融資。本輪融資由Forcefield Ventures、晶泰科技、IMO Ventures和天圖資本領投，方圓資本、德迅投資、雅億資本、新產業創投和博普資本等跟投。

港股異動 | 晶泰控股-P(02228)早盤漲超3% 預期2024年度將達到已商業化公司的收入門檻

招商證券：AI製藥藍海人工智能助力新藥開發全流程

晶泰控股-P02月17日收漲3.63% 主力資金逆市拋售

晶泰控股：2024 年營收預期達 2.5 億港元

晶泰控股預計2024年收入達2.5億港元

晶泰控股-P預期2024年度將達到已商業化公司的收入門檻

晶泰控股(02228.HK)料去年藥物發現及智能自動化解決方案收入達商業化公司收入門檻

阿斯达克财经

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/02228/news?page=8"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"02228","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"02228\",,,,,undefined,":{"symbol":"02228","market":"HK","secType":"STK","nameCN":"晶泰控股-P","latestPrice":4.34,"timestamp":1747280075719,"preClose":4.5,"halted":0,"volume":27285208,"delay":0,"floatShares":4020000000,"shares":4020000000,"eps":-0.8514864421784111,"marketStatus":"交易中","change":-0.16,"latestTime":"05-15 11:34:46","open":4.51,"high":4.51,"low":4.33,"amount":119614306,"amplitude":0.04,"askPrice":4.35,"askSize":49000,"bidPrice":4.34,"bidSize":178000,"shortable":3,"etf":0,"ttmEps":-0.8557783330080032,"tradingStatus":2,"nextMarketStatus":{"tag":"午間休市","tradingStatus":4,"beginTime":1747281600000},"marketStatusCode":2,"adr":0,"listingDate":1718208000000,"exchange":"SEHK","adjPreClose":4.5,"openAndCloseTimeList":[[1747272600000,1747281600000],[1747285200000,1747296000000]],"volumeRatio":1.252176,"lotSize":1000,"spreadScale":0,"tradeCurrency":"HKD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"02228\",,,,,undefined,":{"symbol":"02228","floatShares":4020000000,"roa":"-10.69%","roe":"--","lyrEps":-0.851486,"volumeRatio":1.252176,"shares":4020000000,"dividePrice":0,"high":4.51,"amplitude":0.04,"preClose":4.5,"low":4.33,"week52Low":3.05,"pbRate":"4.06","psRate":"60.45","week52High":16.2,"institutionHeld":0,"latestPrice":4.34,"committee":0.568282,"eps":-0.8514864421784111,"divideRate":0,"volume":27285208,"delay":0,"ttmEps":-0.8557783330080032,"open":4.51,"prevYearClose":5.98,"prevWeekClose":4.63,"prevMonthClose":5.16,"prevQuarterClose":5.89,"fiveDayClose":4.7,"twentyDayClose":4.65,"sixtyDayClose":6.05},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"02228\",pageSize:20,pageCount:8,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2512112718","title":"晶泰控股-P：擬配股籌資約20.88億港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2512112718","media":"新华财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2512112718?lang=zh_tw&edition=fundamental","pubTime":"2025-02-19 08:43","pubTimestamp":1739925839,"startTime":"0","endTime":"0","summary":"新华财经北京2月19日电晶泰控股-P于2月19日早间在港交所公告，当日公司与配售代理订立配售协议，据此，公司同意根据一般授权发行，而配售代理同意（个别而非共同或共同及个别）作为公司的代理，在配售协议的条款及条件规限下，按尽力基准促使承配人按配售价每股配售股份6.1港元认购合共最多3.42亿股配售股份。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202502193322921472.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["02228","BK1141"],"gpt_icon":0},{"id":"2512114753","title":"晶泰控股(02228.HK)折讓5.9%配股 淨籌20.8億元","url":"https://stock-news.laohu8.com/highlight/detail?id=2512114753","media":"阿斯达克财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2512114753?lang=zh_tw&edition=fundamental","pubTime":"2025-02-19 08:32","pubTimestamp":1739925120,"startTime":"0","endTime":"0","summary":"晶泰控股(02228.HK) 公布，配售最多3.42亿股，占扩大后股本约8.52%，每股作价6.1元，较昨日(18日)收市价6.48元折让约5.86%，料净集资最多约20.8亿元。公司相信，现时是筹集额外资金以用于以下用途的适当时机，包括产品持续迭代升级，提升研发技术能力和解决方案能力，数据生成及模型建立；产品商业化及业务发展，加强与从事于与公司类似及互惠互利行业的外部各方及合作伙伴的业务合作，扩大公司的规模及市场份额；潜在机会收购及投资、人才吸引与引进、营运资金补充和一般公司用途。(jl/w)(港股报价延迟最少十五分钟。沽空资料截至 2025-02-18 16:25。)AASTOCKS新闻","market":"sh","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20240611135659493_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20240611135659493_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1418280/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["02228","BK1141"],"gpt_icon":0},{"id":"2512114074","title":"晶泰控股(02228.HK)附屬夥廣東恆健推進AI與產業融合創新聯合體項目","url":"https://stock-news.laohu8.com/highlight/detail?id=2512114074","media":"阿斯达克财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2512114074?lang=zh_tw&edition=fundamental","pubTime":"2025-02-19 08:23","pubTimestamp":1739924580,"startTime":"0","endTime":"0","summary":"晶泰控股(02228.HK) 公布，其公司全资附属深圳晶泰科技近日与广东恒健正积极推进“人工智能+”科技与产业融合创新联合体项目的落地。该项目以“AI+机器人自动化”技术为核心，致力于建设全球领先的研发创新基础设施与产业孵化生态系统，促进战略性产业集群化发展，推动粤港澳大湾区及全球相关产业加速实现数字化和智能化革新，助力大湾区打造世界一流的人工智能研究基础设施，驱动AI医药、新材料、新能源、机器人等产业的未来发展。(jl/w)(港股报价延迟最少十五分钟。沽空资料截至 2025-02-18 16:25。)AASTOCKS新闻","market":"other","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20190724144918944_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20190724144918944_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1418285/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK1141","02228"],"gpt_icon":0},{"id":"2512114575","title":"晶泰控股-P宣佈配售計劃，總籌20.88億港元資金助力產品升級與市場拓展","url":"https://stock-news.laohu8.com/highlight/detail?id=2512114575","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2512114575?lang=zh_tw&edition=fundamental","pubTime":"2025-02-19 08:17","pubTimestamp":1739924223,"startTime":"0","endTime":"0","summary":"配售股份数目相当于本公告日期公司现有已发行股本约9.31%及紧随完成后经扩大已发行股本约8.52%。假设所有约3.42亿股配售股份获悉数认购，完成后，配售将筹集的所得款项总额将约为20.88亿港元，而配售产生的所得款项净额估计约为20.80亿港元。公司将向联交所申请批准配售股份上市及买卖。和讯网站对文中陈述、观点判断保持中立，不对所包含内容的准确性、可靠性或完整性提供任何明示或暗示的保证。请读者仅作参考，并请自行承担全部责任。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502190821369627fdf8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502190821369627fdf8&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1141","02228"],"gpt_icon":1},{"id":"2512411129","title":"晶泰控股-P擬發行最多3.42億股配售股份 淨籌20.8億港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2512411129","media":"新浪港股","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2512411129?lang=zh_tw&edition=fundamental","pubTime":"2025-02-19 08:01","pubTimestamp":1739923260,"startTime":"0","endTime":"0","summary":"　　晶泰控股-P发布公告，于2025年2月19日，本公司与配售代理订立配售协议，本公司同意根据一般授权发行，而配售代理同意作为本公司的代理，在配售协议的条款及条件规限下，按尽力基准促使承配人按配售价每股配售股份6.10港元认购合共最多3.42亿股配售股份。　　假设所有3.42亿股配售股份获悉数认购，于完成后，配售将筹集的所得款项总额将约为20.88亿港元，而配售产生的所得款项净额估计约为20.8亿港元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2025-02-19/doc-inekyhus6046517.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["02228","BK1141"],"gpt_icon":1},{"id":"2512111563","title":"【晶泰控股-P(02228.HK)擬發行最多3.42億股配售股份 淨籌20.8億港元】晶泰控股-P(02228.HK)發佈公告，於2025年2月19日，本公司與配售代理訂立配售協議，本公司同意根據一般授權發行，而配售代理同意(個別而非共同或共同及個別)作為本公司的代理，在配售協議的條款及條件規限下，按盡力基準促使承配人按配售價每股配售股份6.10港元認購合共最多3.42億股配售股份。","url":"https://stock-news.laohu8.com/highlight/detail?id=2512111563","media":"金融界","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2512111563?lang=zh_tw&edition=fundamental","pubTime":"2025-02-19 07:52","pubTimestamp":1739922740,"startTime":"0","endTime":"0","summary":"晶泰控股-P(02228.HK)发布公告，于2025年2月19日，本公司与配售代理订立配售协议，本公司同意根据一般授权发行，而配售代理同意(个别而非共同或共同及个别)作为本公司的代理，在配售协议的条款及条件规限下，按尽力基准促使承配人按配售价每股配售股份6.10港元认购合共最多3.42亿股配售股份。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/02/19075248243797.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK1141","02228"],"gpt_icon":0},{"id":"2512719119","title":"晶泰控股-P(02228)擬發行最多3.42億股配售股份 淨籌20.8億港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2512719119","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2512719119?lang=zh_tw&edition=fundamental","pubTime":"2025-02-19 07:49","pubTimestamp":1739922580,"startTime":"0","endTime":"0","summary":"智通财经APP讯，晶泰控股-P 发布公告，于2025年2月19日，本公司与配售代理订立配售协议，本公司同意根据一般授权发行，而配售代理同意作为本公司的代理，在配售协议的条款及条件规限下，按尽力基准促使承配人按配售价每股配售股份6.10港元认购合共最多3.42亿股配售股份。假设所有3.42亿股配售股份获悉数认购，于完成后，配售将筹集的所得款项总额将约为20.88亿港元，而配售产生的所得款项净额估计约为20.8亿港元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1251409.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1141","02228"],"gpt_icon":1},{"id":"2512111511","title":"【晶泰控股-P(02228.HK)與廣東恆健積極推進“人工智能+”科技與產業融合創新聯合體項目的落地】晶泰控股-P(02228.HK)發佈公告，近日，本公司全資附屬公司深圳晶泰科技有限公司與廣東恆健投資控股有限公司(廣東恆健)正積極推進“人工智能+”科技與產業融合創新聯合體項目(該項目)的落地，該項目以“AI+機器人自動化”技術為核心，致力於建設全球領先的研發創新基礎設施與產業孵化生態系統，促進戰略性產業集羣化發展，推動粵港澳大灣區及全球相關產業加速實現數字化和智能化革新，助力大灣區打造世界一流的人工智能研究基礎設施，驅動AI醫藥、新材料、新能源、機器人等產業的未來發展。","url":"https://stock-news.laohu8.com/highlight/detail?id=2512111511","media":"金融界","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2512111511?lang=zh_tw&edition=fundamental","pubTime":"2025-02-19 07:48","pubTimestamp":1739922504,"startTime":"0","endTime":"0","summary":"晶泰控股-P(02228.HK)发布公告，近日，本公司全资附属公司深圳晶泰科技有限公司与广东恒健投资控股有限公司(广东恒健)正积极推进“人工智能+”科技与产业融合创新联合体项目(该项目)的落地，该项目以“AI+机器人自动化”技术为核心，致力于建设全球领先的研发创新基础设施与产业孵化生态系统，促进战略性产业集群化发展，推动粤港澳大湾区及全球相关产业加速实现数字化和智能化革新，助力大湾区打造世界一流的人工智能研究基础设施，驱动AI医药、新材料、新能源、机器人等产业的未来发展。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/02/19074848243779.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["02228","399941","BK1141","159938","09939","159703","000941.SH","BK1515","BK1161","BK1574","159875","159983","161631","160640"],"gpt_icon":0},{"id":"2512813513","title":"晶泰控股-P02月18日主力淨流出5190萬元 散戶資金買入","url":"https://stock-news.laohu8.com/highlight/detail?id=2512813513","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2512813513?lang=zh_tw&edition=fundamental","pubTime":"2025-02-18 16:16","pubTimestamp":1739866597,"startTime":"0","endTime":"0","summary":"02月18日, 晶泰控股-P股价跌5.40%，报收6.48元，成交金额11.89亿元，换手率4.82%，振幅12.55%，量比0.91。晶泰控股-P今日主力资金净流出5190万元，上一交易日主力净流出7084万元。该股近5个交易日下跌3.28%，主力资金累计净流出1.23亿元，其中1个交易日为股价上涨时净流出；近20日主力资金累计净流入1.07亿元，其中净流入天数为10日。该股主力净额占比0.22%，港股市场排名2624/2650。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250218161724a24a46bb&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250218161724a24a46bb&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02228","BK1141"],"gpt_icon":1},{"id":"2512189707","title":"晶泰控股－Ｐ(02228)出現大手賣出110萬股，成交價$6.5，涉資715萬","url":"https://stock-news.laohu8.com/highlight/detail?id=2512189707","media":"阿斯达克财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2512189707?lang=zh_tw&edition=fundamental","pubTime":"2025-02-18 13:55","pubTimestamp":1739858100,"startTime":"0","endTime":"0","summary":"[大手成交]晶泰控股－Ｐ(02228)在下午01:55出现大手卖出，成交量为110万，成交价为港币$6.5，涉资715万。至目前为止，股价跌5.109%，今日最高价为$7.14，而最低价为$6.5，总成交量为1.221亿股，总成交金额港币$8.353亿。","market":"sh","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20180205145555799_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20180205145555799_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAT2502189001/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK1141","02228"],"gpt_icon":0},{"id":"2512166186","title":"晶泰控股-P(02228)下跌5.11%，報6.5元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2512166186","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2512166186?lang=zh_tw&edition=fundamental","pubTime":"2025-02-18 13:38","pubTimestamp":1739857124,"startTime":"0","endTime":"0","summary":"2月18日，晶泰控股-P(02228)盘中下跌5.11%，截至13:38，报6.5元/股，成交7.88亿元。晶泰控股有限公司主要以量子物理、人工智能和机器人技术为基础，为全球制药、材料科学等领域提供研发解决方案及服务。公司运用量子物理原理、先进的AI技术、高性能云计算以及可扩展和标准化的机器人自动化等技术，服务于农业技术、能源、新型化学品以及化妆品等行业。截至2024年中报，晶泰控股-P营业总收入1.03亿元、净利润-12.37亿元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.jrj.com.cn/2025/02/18133848221643.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["02228","BK1141"],"gpt_icon":0},{"id":"2512148186","title":"晶泰控股-P盤中異動 快速下挫5.11%報6.500港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2512148186","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2512148186?lang=zh_tw&edition=fundamental","pubTime":"2025-02-18 13:37","pubTimestamp":1739857022,"startTime":"0","endTime":"0","summary":"2025年02月18日下午盘13时37分，晶泰控股-P股票出现波动，股价急速下跌5.11%。截至发稿，该股报6.500港元/股，成交量1.12554亿股，换手率3.06%，振幅9.34%。资金方面，该股资金流入2.87112亿港元，流出3.5994亿港元。晶泰控股-P股票所在的生物技术行业中，整体涨幅为1.15%。该信息摘要如下： 晶泰控股-P 发布公告称，集团预计截至 2024 年 12 月 31 日止年度，通过提供药物发现解决方案及智能自动化解决方案产生的收入能达到 2.5 亿港元这一已商业化公司的收入门槛。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025021813370296271014&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025021813370296271014&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1141","02228"],"gpt_icon":1},{"id":"2512249902","title":"【默達生物獲上億元人民幣A輪融資】深圳默達生物科技有限公司（META Pharmaceuticals Inc.）近日宣佈完成上億元人民幣的A輪融資。本輪融資由Forcefield Ventures、晶泰科技、IMO Ventures和天圖資本領投，方圓資本、德迅投資、雅億資本、新產業創投和博普資本等跟投。","url":"https://stock-news.laohu8.com/highlight/detail?id=2512249902","media":"金融界","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2512249902?lang=zh_tw&edition=fundamental","pubTime":"2025-02-18 11:23","pubTimestamp":1739849027,"startTime":"0","endTime":"0","summary":"深圳默达生物科技有限公司（META Pharmaceuticals Inc.）近日宣布完成上亿元人民币的A轮融资。本轮融资由Forcefield Ventures、晶泰科技、IMO Ventures和天图资本领投，方圆资本、德迅投资、雅亿资本、新产业创投和博普资本等跟投。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/02/18112348218626.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["LU1732799900.SGD","LU2462157665.USD","LU0354030511.USD","LU0545039389.USD","IE00B4JS1V06.HKD","LU2430703251.USD","LU2764262908.HKD","LU0234572021.USD","LU1066051498.USD","02228","SG9999014898.SGD","LU0878866978.SGD","LU0011850046.USD","LU0985320562.USD","SGXZ99366536.SGD","LU0225283273.USD","LU0345769128.USD","LU0061475181.USD","LU0082616367.USD","LU0157215616.USD","LU0097036916.USD","IE00BK4W5M84.HKD","IE00BJTD4V19.USD","IE00B7KXQ091.USD","BK0239","LU0912757837.SGD","LU1201861249.SGD","LU1242518931.SGD","IMO","LU1852331112.SGD","SGXZ31699556.SGD","159837","LU1868837136.USD","LU2133065610.SGD","LU2213496289.HKD","LU2720916845.USD","300832","LU1127390331.HKD","LU1814569148.SGD","LU1778281490.HKD","LU0109391861.USD","LU1988902786.USD","LU0353189680.USD","GB00B4QBRK32.GBP","BK4592","LU0553294199.USD","LU0795875169.SGD","LU0949170772.SGD","LU1642822529.SGD"],"gpt_icon":0},{"id":"2512901346","title":"港股異動 | 晶泰控股-P(02228)早盤漲超3% 預期2024年度將達到已商業化公司的收入門檻","url":"https://stock-news.laohu8.com/highlight/detail?id=2512901346","media":"智通财经","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2512901346?lang=zh_tw&edition=fundamental","pubTime":"2025-02-18 10:35","pubTimestamp":1739846117,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，晶泰控股-P(02228)早盘涨超3%，截至发稿，涨3.65%，报7.1港元，成交额3.2亿港元。消息面上，晶泰控股-P发布公告，集团预期截至2024年12月31日止年度透过提供药物发现解决方案及智能自动化解决方案所产生的收入将达到已商业化公司(定义见上市规则第18C章)的收入门槛，即2.5亿港元。该等收入乃由于本集团于截至2024年12月31日止年度的业务发展及市场机遇所致。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1250980.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02228","BK1141"],"gpt_icon":0},{"id":"2512912788","title":"招商證券：AI製藥藍海 人工智能助力新藥開發全流程","url":"https://stock-news.laohu8.com/highlight/detail?id=2512912788","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2512912788?lang=zh_tw&edition=fundamental","pubTime":"2025-02-17 16:47","pubTimestamp":1739782033,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，招商证券发布研报称，目前人工智能技术在药物研发过程中的应用主要集中于药物发现阶段，随着Deepseek等大模型技术应用，AI在临床阶段的应用价值也将逐渐得到体现。招商证券主要观点如下：AI可用于新药开发全过程，达到降低成本，增加药物研发可能性目的。全球AI制药行业投融资活跃，MNC 参与达成多项重磅交易。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1250656.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1576","BK0028","BK0183","BK1191","03759","BK1141","01873","BK1564","02228","161631","BK0276","01477","600999","06099","BK1574","BK0010","BK0188","BK1147","BK0012"],"gpt_icon":1},{"id":"2512114729","title":"晶泰控股-P02月17日收漲3.63% 主力資金逆市拋售","url":"https://stock-news.laohu8.com/highlight/detail?id=2512114729","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2512114729?lang=zh_tw&edition=fundamental","pubTime":"2025-02-17 16:17","pubTimestamp":1739780223,"startTime":"0","endTime":"0","summary":"02月17日, 晶泰控股-P股价涨3.63%，报收6.85元，成交金额13.37亿元，换手率5.36%，振幅10.44%，量比0.91。晶泰控股-P今日主力资金净流出7084万元，上一交易日主力净流入1.02亿元。该股近5个交易日上涨1.48%，主力资金累计净流出1.37亿元；近20日主力资金累计净流入1.58亿元，其中净流入天数为10日。该股主力净额占比0.28%，港股市场排名2635/2651。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250217161813a248ebd1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250217161813a248ebd1&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1141","02228"],"gpt_icon":1},{"id":"2512225967","title":"晶泰控股：2024 年營收預期達 2.5 億港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2512225967","media":"和讯网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2512225967?lang=zh_tw&edition=fundamental","pubTime":"2025-02-17 09:54","pubTimestamp":1739757285,"startTime":"0","endTime":"0","summary":"【晶泰控股-P 预期 2024 年年度收入将达 2.5 亿港元】 晶泰控股-P 发布公告称，集团预计截至 2024 年 12 月 31 日止年度，通过提供药物发现解决方案及智能自动化解决方案产生的收入能达到 2.5 亿港元这一已商业化公司的收入门槛。 这一收入是由于集团在截至 2024 年 12 月 31 日止年度的业务发展及市场机遇所致。【免责声明】本文仅代表作者本人观点，与和讯网无关。和讯网站对文中陈述、观点判断保持中立，不对所包含内容的准确性、可靠性或完整性提供任何明示或暗示的保证。请读者仅作参考，并请自行承担全部责任。邮箱：news_center@staff.hexun.com","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250217100526988808f1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250217100526988808f1&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02228"],"gpt_icon":0},{"id":"2512964957","title":"晶泰控股預計2024年收入達2.5億港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2512964957","media":"财中社","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2512964957?lang=zh_tw&edition=fundamental","pubTime":"2025-02-17 09:35","pubTimestamp":1739756153,"startTime":"0","endTime":"0","summary":"晶泰控股-P（02228）发布公告，预计截至2024年12月31日止年度，通过提供药物发现解决方案及智能自动化解决方案所产生的收入将达到2.5亿港元。这一预期收入的增长主要得益于公司在业务发展及市场机遇方面的良好表现。公告中提到的收入数据基于公司管理层的初步评估，尚未经过审计，实际业绩可能会有所不同。此外，公告指出，截止目前，公司仍被视为尚未商业化公司。若未来获得联交所通知不再被视为尚未商业化公司，晶泰控股将会适时发布进一步公告。投资者在交易公司证券时需保持谨慎，关注未来的业绩发布。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025021709361296259c20&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025021709361296259c20&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02228","BK1141"],"gpt_icon":0},{"id":"2512966004","title":"晶泰控股-P預期2024年度將達到已商業化公司的收入門檻","url":"https://stock-news.laohu8.com/highlight/detail?id=2512966004","media":"新浪港股","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2512966004?lang=zh_tw&edition=fundamental","pubTime":"2025-02-17 08:44","pubTimestamp":1739753040,"startTime":"0","endTime":"0","summary":"热点栏目\n\n自选股\n数据中心\n行情中心\n资金流向\n模拟交易\n\n客户端\n\n\n　　晶泰控股-P（02228）发布公告，集团预期截至2024年12月31日止年度透过提供药物发现解决方案及智能自动化解决方案所产生的收入将达到已商业化公司（定义见上市规则第18C章）的收入门槛，即2.5亿港元。该等收入乃由于本集团于截至2024年12月31日止年度的业务发展及市场机遇所致。\n\n\n\n海量资讯、精准解读，尽在新浪财经APP\n\n责任编辑：卢昱君","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2025-02-17/doc-inektywp5001930.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1141","02228"],"gpt_icon":0},{"id":"2512694489","title":"晶泰控股(02228.HK)料去年藥物發現及智能自動化解決方案收入達商業化公司收入門檻","url":"https://stock-news.laohu8.com/highlight/detail?id=2512694489","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2512694489?lang=zh_tw&edition=fundamental","pubTime":"2025-02-17 08:34","pubTimestamp":1739752440,"startTime":"0","endTime":"0","summary":"晶泰控股-P(02228.HK) 公布，预期去年透过提供药物发现解决方案及智能自动化解决方案所产生的收入，将达到已商业化公司的收入门槛，即2.5亿元，乃由于集团去年业务发展及市场机遇所致。(jl/da)(港股报价延迟最少十五分钟。沽空资料截至 2025-02-14 16:25。)AASTOCKS新闻","market":"hk","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20240611135701030_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20240611135701030_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1417643/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK1141","02228"],"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":8,"totalSize":200,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/02228\",params:#limit:5,,,undefined,":[{"date":"2025-03-28","symbol":"02228","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1743125400000,"name":null,"time":"","dateTimestamp":1743091200000,"actualEps":null},{"date":"2024-08-28","symbol":"02228","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1724808600000,"name":null,"time":"","dateTimestamp":1724774400000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"02228\",market:\"HK\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"02228\",market:\"HK\",delay:false,,,undefined,":{"strongBuy":0.3333,"buy":0.6667,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.6667,"analysts":3,"updateTime":1742313600000},"@#url:\"https://hq.skytigris.cn/hkstock/value_analysis/stock/02228\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"02228","date":"2025-05-14","current":-8.240535,"percent":0.674107,"low":-19.121462,"twenty":-11.321925,"median":-8.892407,"eighty":-6.807272,"high":-4.071689,"avg":-9.331711,"sd":2.959567,"marketCap":18089152924},"quantilePoints":[{"date":"2024-06-14","current":-8.922014,"twenty":-9.439723,"median":-9.245582,"eighty":-9.051441,"marketCap":18396572909},{"date":"2024-06-21","current":-8.857946,"twenty":-8.9092,"median":-8.775161,"eighty":-8.737522,"marketCap":18226234271},{"date":"2024-06-28","current":-8.745676,"twenty":-8.918198,"median":-8.816527,"eighty":-8.750223,"marketCap":17987760178},{"date":"2024-07-05","current":-8.747576,"twenty":-8.902934,"median":-8.771787,"eighty":-8.744343,"marketCap":17987760178},{"date":"2024-07-12","current":-9.049063,"twenty":-8.902934,"median":-8.775161,"eighty":-8.741587,"marketCap":18635047002},{"date":"2024-07-19","current":-9.247407,"twenty":-9.172529,"median":-8.857489,"eighty":-8.744343,"marketCap":19043859733},{"date":"2024-07-26","current":-9.575773,"twenty":-9.510189,"median":-8.892407,"eighty":-8.745676,"marketCap":19793349741},{"date":"2024-08-02","current":-9.235042,"twenty":-9.509847,"median":-8.912474,"eighty":-8.745676,"marketCap":19077927461},{"date":"2024-08-09","current":-9.468775,"twenty":-9.510189,"median":-8.974725,"eighty":-8.747576,"marketCap":19691146558},{"date":"2024-08-16","current":-10.464009,"twenty":-9.56947,"median":-9.142341,"eighty":-8.760904,"marketCap":21769277942},{"date":"2024-08-23","current":-10.517808,"twenty":-9.632925,"median":-9.235042,"eighty":-8.768412,"marketCap":21973684308},{"date":"2024-08-30","current":-10.371399,"twenty":-10.303269,"median":-9.325095,"eighty":-8.775161,"marketCap":28923500740},{"date":"2024-09-06","current":-18.461728,"twenty":-10.496901,"median":-9.468775,"eighty":-8.776023,"marketCap":51510404146},{"date":"2024-09-13","current":-17.236995,"twenty":-10.891661,"median":-9.521964,"eighty":-8.857032,"marketCap":47967360474},{"date":"2024-09-20","current":-16.063353,"twenty":-11.51195,"median":-9.559061,"eighty":-8.857763,"marketCap":44969400445},{"date":"2024-09-27","current":-15.483466,"twenty":-14.686278,"median":-9.575773,"eighty":-8.860072,"marketCap":43606691340},{"date":"2024-10-04","current":-13.755671,"twenty":-14.947547,"median":-9.615329,"eighty":-8.879685,"marketCap":38564667654},{"date":"2024-10-10","current":-12.348216,"twenty":-14.780027,"median":-9.846626,"eighty":-8.896618,"marketCap":34408404886},{"date":"2024-10-18","current":-11.446606,"twenty":-14.586898,"median":-10.272952,"eighty":-8.910566,"marketCap":31717054404},{"date":"2024-10-25","current":-12.086709,"twenty":-14.247622,"median":-10.371399,"eighty":-8.935918,"marketCap":33488576240},{"date":"2024-11-01","current":-11.046421,"twenty":-13.547793,"median":-10.507354,"eighty":-8.963954,"marketCap":30626887121},{"date":"2024-11-08","current":-8.233542,"twenty":-13.084166,"median":-10.464009,"eighty":-8.959678,"marketCap":22655038860},{"date":"2024-11-15","current":-6.674421,"twenty":-12.818197,"median":-10.331022,"eighty":-8.873325,"marketCap":18226234271},{"date":"2024-11-22","current":-5.092957,"twenty":-12.605094,"median":-9.956054,"eighty":-8.775506,"marketCap":13899632864},{"date":"2024-11-29","current":-4.071689,"twenty":-12.362191,"median":-9.633447,"eighty":-8.746436,"marketCap":11106079200},{"date":"2024-12-06","current":-6.234627,"twenty":-12.309524,"median":-9.607633,"eighty":-8.729287,"marketCap":16965728349},{"date":"2024-12-13","current":-4.937116,"twenty":-12.241743,"median":-9.572622,"eighty":-8.309283,"marketCap":13422684678},{"date":"2024-12-20","current":-6.992956,"twenty":-12.176011,"median":-9.548971,"eighty":-7.374004,"marketCap":18907588823},{"date":"2024-12-27","current":-7.61626,"twenty":-12.099333,"median":-9.521964,"eighty":-6.992956,"marketCap":20576907476},{"date":"2025-01-03","current":-6.613619,"twenty":-12.089234,"median":-9.489311,"eighty":-6.978437,"marketCap":17885556995},{"date":"2025-01-10","current":-5.450117,"twenty":-12.058756,"median":-9.391379,"eighty":-6.644107,"marketCap":14683190599},{"date":"2025-01-17","current":-5.875315,"twenty":-12.04248,"median":-9.241225,"eighty":-6.25569,"marketCap":15841493338},{"date":"2025-01-24","current":-6.177753,"twenty":-11.949888,"median":-9.172529,"eighty":-6.11967,"marketCap":16761321984},{"date":"2025-01-28","current":-6.498305,"twenty":-11.921589,"median":-9.112153,"eighty":-6.130311,"marketCap":17715218357},{"date":"2025-02-07","current":-7.424154,"twenty":-11.872333,"median":-8.96938,"eighty":-6.148709,"marketCap":20134027017},{"date":"2025-02-14","current":-8.323374,"twenty":-11.760531,"median":-8.922014,"eighty":-6.178085,"marketCap":22518767950},{"date":"2025-02-21","current":-10.607329,"twenty":-11.720414,"median":-8.939394,"eighty":-6.187416,"marketCap":28855365285},{"date":"2025-02-28","current":-8.380735,"twenty":-11.643652,"median":-8.964036,"eighty":-6.222464,"marketCap":22723174315},{"date":"2025-03-07","current":-8.409794,"twenty":-11.556185,"median":-8.912474,"eighty":-6.239893,"marketCap":22893512953},{"date":"2025-03-14","current":-8.131514,"twenty":-11.5122,"median":-8.860603,"eighty":-6.269085,"marketCap":22144022946},{"date":"2025-03-21","current":-7.997044,"twenty":-11.440339,"median":-8.816527,"eighty":-6.340941,"marketCap":21769277942},{"date":"2025-03-28","current":-9.307254,"twenty":-11.391935,"median":-8.776023,"eighty":-6.503525,"marketCap":25284615976},{"date":"2025-04-03","current":-13.220486,"twenty":-11.563082,"median":-8.857032,"eighty":-6.524404,"marketCap":21465794803},{"date":"2025-04-11","current":-11.616184,"twenty":-11.563082,"median":-8.876505,"eighty":-6.613619,"marketCap":18692124688},{"date":"2025-04-17","current":-8.481901,"twenty":-11.535495,"median":-8.876505,"eighty":-6.644107,"marketCap":18290143512},{"date":"2025-04-25","current":-9.200975,"twenty":-11.479403,"median":-8.897671,"eighty":-6.665344,"marketCap":19857870099},{"date":"2025-05-02","current":-9.49742,"twenty":-11.434072,"median":-8.939394,"eighty":-6.691701,"marketCap":20541238098},{"date":"2025-05-09","current":-8.545306,"twenty":-11.391935,"median":-8.912474,"eighty":-6.740034,"marketCap":18611728453},{"date":"2025-05-14","current":-8.240535,"twenty":-11.321925,"median":-8.892407,"eighty":-6.807272,"marketCap":18089152924}],"updateTime":1747280086603}}}